A Phase II Study Of PS-341 [bortezomib] (NSC 681239) In Patients With Untreated Or Relapsed Mantle Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Mar 2010 Actual end date (1 Dec 2009) added as reproted by ClinicalTrials.gov record.
- 11 Sep 2009 Planned end date (28 Jul 2004) added as reported by National Cancer Institute of Canada.